Last reviewed · How we verify
Interferon-β [IFN-β]
Interferon-β binds to the interferon receptor, activating a signaling cascade that modulates the immune response.
Interferon-β binds to the interferon receptor, activating a signaling cascade that modulates the immune response. Used for Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis.
At a glance
| Generic name | Interferon-β [IFN-β] |
|---|---|
| Also known as | Avonex®, Rebif®, Betaseron® |
| Sponsor | Sanofi |
| Drug class | Interferon |
| Target | Interferon receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Interferon-β is a type I interferon that plays a key role in the innate immune response, particularly in the activation of macrophages and the induction of antiviral and antiproliferative proteins.
Approved indications
- Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon-β [IFN-β] CI brief — competitive landscape report
- Interferon-β [IFN-β] updates RSS · CI watch RSS
- Sanofi portfolio CI